TRAF6-Ubc13 Inhibitors Disrupt NF-kB Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies lack effective inhibitors to target the protein-protein interaction between TRAF6 (E3 ligase) and Ubc13 (E2 enzyme), which is crucial for regulating NF-κB activation and is implicated in various diseases such as autoimmune disorders and cancer.
Innovation Solution
Development of novel compounds according to Formulas I, II, III, IV, and XX, which specifically target the TRAF6-Ubc13 interaction, thereby disrupting the E2-E3 ubiquitination pathway and reducing NF-κB activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRAF6-Ubc13 interaction is inhibited, then NF-κB activation is reduced and disease progression is slowed, but the complexity of developing specific inhibitors increases
Solution Approach 1:
The patent uses small molecule compounds as intermediary substances that bind to the TRAF6-Ubc13 interaction interface, disrupting the protein-protein interaction. These compounds act as mediators that prevent the E3 ligase from activating NF-κB, thereby treating diseases without directly modifying the complex protein machinery.
Solution Approach 2:
The patent modifies molecular parameters by creating compounds with specific chemical structures (Formulas I-IV and XX) that optimize binding affinity to TRAF6 while maintaining selectivity. By adjusting molecular weight, functional groups, and spatial configuration, the inhibitors achieve effective disruption of the interaction pathway.
2Reliability
If TRAF6 activity is disrupted, then ubiquitination pathway is inhibited and NF-κB activation is reduced, but the difficulty of achieving selective inhibition increases
Solution Approach 1:
The patent achieves selective inhibition by designing compounds that specifically target the TRAF6-Ubc13 interaction interface rather than broadly inhibiting ubiquitination. The local quality of the inhibitor binding site allows precise disruption of this specific interaction, avoiding off-target effects on other E3 ligases or ubiquitination pathways.
Solution Approach 2:
The patent creates molecular copies or analogs of the TRAF6-Ubc13 interface that mimic the protein-protein interaction geometry. By designing compounds that replicate the spatial arrangement of the interaction interface, the inhibitors effectively compete with and disrupt the natural binding between TRAF6 and Ubc13.
Data Source
AI summary
The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.